Log in
Enquire now
‌

US Patent 10201527 Benzimidazole derivatives: preparation and pharmaceutical applications

Patent 10201527 was granted and assigned to MEI Pharma on February, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
MEI Pharma
MEI Pharma
0
Current Assignee
MEI Pharma
MEI Pharma
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
102015270
Patent Inventor Names
Yong Zou0
Eric T. Sun0
Hong Yan Song0
Niefang Yu0
DiZhong Chen0
Date of Patent
February 12, 2019
0
Patent Application Number
156126700
Date Filed
June 2, 2017
0
Patent Citations Received
‌
US Patent 10626092 Polymorphic forms of 3-[(2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxy-acrylamide and uses thereof
Patent Primary Examiner
‌
Shirley V Gembeh
0
Patent abstract

The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to benzimidazole containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with dysregulation of histone deacetylase (HDAC).

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10201527 Benzimidazole derivatives: preparation and pharmaceutical applications

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us